HLS Therapeutics Inc. (OTCMKTS:HLTRF) Shares Shorted: Short Interest Down 93.5% in September

Posted by Latisha Jones on Oct 11th, 2026

HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) was the target of a large drop in short interest during the month of September. As of September 30th, there was short interest totaling 100 shares, a drop of 93.5% from the September 15th total of 1,546 shares. Based on an average daily trading volume, of 927 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analysts Forecast Growth

Separately, Raymond James Financial upgraded HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a research note on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating. According to MarketBeat.com, the company has an average rating of “Strong Buy”.

Check Out Our Latest Analysis on HLTRF

HLS Therapeutics Price Performance

Shares of HLTRF remained flat at $2.75 during trading hours on Friday. The stock’s 50 day simple moving average is $2.78 and its 200-day simple moving average is $3.03. HLS Therapeutics has a twelve month low of $2.64 and a twelve month high of $4.02.

About HLS Therapeutics

(Get Free Report)

HLS Therapeutics Inc is a specialty pharmaceutical company focused on acquiring, developing and commercializing medicines in Canada and the United States. The company concentrates on products that address significant medical needs, with an emphasis on central nervous system and cardiovascular therapies.

HLS has commercialized branded prescription medicines and specialty products through partnerships, licensing arrangements and acquired product rights. Its portfolio has included Clozaril (clozapine), a treatment used in schizophrenia, as well as other therapies marketed through specialty-care and hospital channels.